JP2020511672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511672A5 JP2020511672A5 JP2019568816A JP2019568816A JP2020511672A5 JP 2020511672 A5 JP2020511672 A5 JP 2020511672A5 JP 2019568816 A JP2019568816 A JP 2019568816A JP 2019568816 A JP2019568816 A JP 2019568816A JP 2020511672 A5 JP2020511672 A5 JP 2020511672A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hla class
- binding
- subject
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 113
- 102000004196 processed proteins & peptides Human genes 0.000 claims 111
- 229920001184 polypeptide Polymers 0.000 claims 107
- 239000000427 antigen Substances 0.000 claims 47
- 102000036639 antigens Human genes 0.000 claims 47
- 108091007433 antigens Proteins 0.000 claims 47
- 210000001744 T-lymphocyte Anatomy 0.000 claims 42
- 230000027455 binding Effects 0.000 claims 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 29
- 239000004480 active ingredient Substances 0.000 claims 26
- 238000000034 method Methods 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 21
- 201000011510 cancer Diseases 0.000 claims 17
- 230000004044 response Effects 0.000 claims 16
- 230000005867 T cell response Effects 0.000 claims 8
- 230000028993 immune response Effects 0.000 claims 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 230000000112 colonic effect Effects 0.000 claims 2
- 208000030381 cutaneous melanoma Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000000867 larynx Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000000088 lip Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 210000001989 nasopharynx Anatomy 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 235000002566 Capsicum Nutrition 0.000 claims 1
- 240000008574 Capsicum frutescens Species 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 239000001390 capsicum minimum Substances 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 230000009149 molecular binding Effects 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 201000002131 testis sarcoma Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17159242.1A EP3369431A1 (en) | 2017-03-03 | 2017-03-03 | Vaccine |
| EP17159242.1 | 2017-03-03 | ||
| EP17159243.9 | 2017-03-03 | ||
| EP17159243.9A EP3370065A1 (en) | 2017-03-03 | 2017-03-03 | Immunogenic peptides |
| GBGB1703809.2A GB201703809D0 (en) | 2017-03-09 | 2017-03-09 | Vaccine |
| GB1703809.2 | 2017-03-09 | ||
| PCT/EP2018/055232 WO2018158457A1 (en) | 2017-03-03 | 2018-03-02 | Population-based immunogenic peptide identification platform |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511672A JP2020511672A (ja) | 2020-04-16 |
| JP2020511672A5 true JP2020511672A5 (enExample) | 2021-04-15 |
| JP7437939B2 JP7437939B2 (ja) | 2024-02-26 |
Family
ID=61386864
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568814A Active JP7751374B2 (ja) | 2017-03-03 | 2018-03-02 | ペプチドワクチン |
| JP2019568816A Active JP7437939B2 (ja) | 2017-03-03 | 2018-03-02 | 集団に基づいた免疫原性ペプチドの同定のプラットフォーム |
| JP2019568815A Active JP7831948B2 (ja) | 2017-03-03 | 2018-03-02 | 個別化された免疫原性ペプチドの同定のプラットフォーム |
| JP2022197534A Pending JP2023051941A (ja) | 2017-03-03 | 2022-12-09 | ペプチドワクチン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568814A Active JP7751374B2 (ja) | 2017-03-03 | 2018-03-02 | ペプチドワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568815A Active JP7831948B2 (ja) | 2017-03-03 | 2018-03-02 | 個別化された免疫原性ペプチドの同定のプラットフォーム |
| JP2022197534A Pending JP2023051941A (ja) | 2017-03-03 | 2022-12-09 | ペプチドワクチン |
Country Status (16)
| Country | Link |
|---|---|
| US (9) | US20180264094A1 (enExample) |
| EP (3) | EP3589951A1 (enExample) |
| JP (4) | JP7751374B2 (enExample) |
| KR (4) | KR102549625B1 (enExample) |
| CN (4) | CN110651188B (enExample) |
| AU (3) | AU2018226566B2 (enExample) |
| BR (3) | BR112019018307A2 (enExample) |
| CA (3) | CA3054871A1 (enExample) |
| CL (4) | CL2019002534A1 (enExample) |
| CO (3) | CO2019010524A2 (enExample) |
| IL (3) | IL268919B2 (enExample) |
| MA (3) | MA47683A (enExample) |
| MX (3) | MX2019010460A (enExample) |
| SG (3) | SG11201906765UA (enExample) |
| WO (3) | WO2018158457A1 (enExample) |
| ZA (2) | ZA201904725B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2980039A1 (en) * | 2015-03-20 | 2016-09-29 | Children's National Medical Center | Generating virus or other antigen-specific t cells from a naive t cell population |
| BR112019018307A2 (pt) | 2017-03-03 | 2020-03-31 | Treos Bio Zrt | Plataforma para identificação de peptídeos imunogênicos baseada em população |
| CN113329761A (zh) | 2018-09-04 | 2021-08-31 | 特雷斯生物有限公司 | 肽疫苗 |
| GB201814361D0 (en) * | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Immunogenetic cancer screening test |
| GB201814362D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
| US11945850B2 (en) * | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| TW202039535A (zh) * | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| EP4100051A2 (en) * | 2020-02-07 | 2022-12-14 | ISA Pharmaceuticals B.V. | Treatment of hpv-related diseases |
| KR102159921B1 (ko) * | 2020-03-24 | 2020-09-25 | 주식회사 테라젠바이오 | 펩타이드 서열 및 hla 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램 |
| JP2023520562A (ja) * | 2020-04-03 | 2023-05-17 | ペップティーシー ヴァクシーンズ リミテッド | コロナウイルスワクチン |
| GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
| AU2020443560B2 (en) * | 2020-04-20 | 2024-03-21 | Nec Corporation | A method and a system for optimal vaccine design |
| CN112048001B (zh) * | 2020-09-08 | 2022-04-05 | 南方科技大学 | 一种肿瘤新生抗原多肽及其应用 |
| CN116601713A (zh) * | 2020-09-12 | 2023-08-15 | 阿斯利康(英国)有限公司 | 用于抗her2抗体-药物缀合物疗法的评分方法 |
| KR102278727B1 (ko) * | 2020-09-16 | 2021-07-19 | 주식회사 테라젠바이오 | 대상 암 조직 및 세포 유리형 dna 유래 펩타이드 서열 및 hla 클래스 ii 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램 |
| WO2023017768A1 (ja) | 2021-08-10 | 2023-02-16 | 日本電気株式会社 | 情報処理システム及び情報処理方法 |
| TWI898159B (zh) | 2021-10-04 | 2025-09-21 | 日商日本電氣股份有限公司 | 管理方法、管理系統及電子健康紀錄系統 |
| WO2023059606A1 (en) * | 2021-10-06 | 2023-04-13 | Cancervax, Inc. | Methods and compositions for cancer treatment |
| EP4516932A4 (en) * | 2022-04-27 | 2026-04-29 | Postech Res & Business Dev Found | METHOD FOR CONSTRUCTING PEPTIDE-NUCLEIC ACID HYBRID MOLECULES FROM HOT SPOTS BASED ON IN VITRO SELECTION |
| CN115785203B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标10及其用途 |
| CN119731659A (zh) | 2022-08-17 | 2025-03-28 | 日本电气株式会社 | 信息处理系统、信息处理方法及程序 |
| GB202216453D0 (en) | 2022-11-04 | 2022-12-21 | Lisziewicz Julianna | Identification of antigens which induce t-cell responses |
| JP7835418B1 (ja) * | 2025-01-14 | 2026-03-25 | 国立大学法人神戸大学 | がんワクチンの効果予測 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| EP0914142B9 (en) | 1996-03-11 | 2012-01-04 | Epimmune Inc. | Peptides with increased binding affinity for at least three hla-a3-like molecules |
| US6617434B1 (en) * | 1996-05-31 | 2003-09-09 | North Shore Long Island Jewish Research Institute | Identificiaton of differentially methylated and mutated nucleic acids |
| US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
| JP3876002B2 (ja) * | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
| AUPQ776100A0 (en) | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
| US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| EP1545610A4 (en) | 2002-09-06 | 2006-11-08 | Mannkind Corp | EPITOPE SEQUENCES |
| GB0228900D0 (en) * | 2002-12-11 | 2003-01-15 | Ml Lab Plc | Cancer Immunotherapy |
| US20060257852A1 (en) | 2003-04-10 | 2006-11-16 | Chiron Corporation | Severe acute respiratory syndrome coronavirus |
| WO2004093808A2 (en) * | 2003-04-22 | 2004-11-04 | Maxygen, Inc. | Novel tumor-associated antigens |
| US20050100883A1 (en) | 2003-11-12 | 2005-05-12 | Wang Chang Y. | Peptide-based diagnostic reagents for SARS |
| CN1910284B (zh) * | 2004-01-20 | 2011-04-06 | 爱知县 | 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用 |
| CA2566506A1 (en) | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
| WO2006080142A1 (ja) | 2005-01-25 | 2006-08-03 | Nec Corporation | Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター |
| DK1853305T3 (en) | 2005-02-04 | 2014-12-01 | Survac Aps | Survivin-peptide vaccine |
| CN100402554C (zh) | 2005-02-25 | 2008-07-16 | 李玉新 | 睾丸特异性蛋白50人源抗体的制备及用途 |
| FR2891462B1 (fr) | 2005-09-30 | 2009-10-16 | Commissariat Energie Atomique | Epitopes t cd4+ de la survivine et leurs applications |
| GB0520067D0 (en) | 2005-10-01 | 2005-11-09 | Cancer Rec Tech Ltd | Treatment of cancer |
| CA2665816C (en) * | 2006-09-21 | 2016-07-12 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
| CA2700573C (en) | 2006-09-26 | 2016-11-22 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| EP2155782A2 (en) | 2007-03-26 | 2010-02-24 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| EP2042600A1 (en) | 2007-09-28 | 2009-04-01 | Commissariat A L'energie Atomique | A public and immunogenic CD4+ T Cell epitope of the hiv tat protein and its applications |
| AU2009232774B2 (en) | 2008-03-31 | 2014-05-29 | Tella Inc. | Partial peptide of Survivin presented on MHC class II molecule and use thereof |
| PT2119726E (pt) | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| TW201008574A (en) * | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| GB0818065D0 (en) * | 2008-10-02 | 2008-11-05 | Cancer Rec Tech Ltd | Immunogenic peptides and uses thereof |
| US20120244145A1 (en) * | 2009-11-16 | 2012-09-27 | Duke University | Enhanced immunological responses |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| US20170039314A1 (en) * | 2010-03-23 | 2017-02-09 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| WO2012051282A2 (en) | 2010-10-14 | 2012-04-19 | The Ohio State University Research Foundation | Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy |
| EP2745845A1 (en) | 2012-12-19 | 2014-06-25 | Centre Hospitalier Universitaire de Bordeaux | A method for preventing or treating an HIV infection |
| LT2945647T (lt) * | 2013-01-15 | 2021-02-25 | Memorial Sloan Kettering Cancer Center | Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai |
| WO2014180490A1 (en) * | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| EA201690912A1 (ru) * | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| WO2015143335A1 (en) | 2014-03-20 | 2015-09-24 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric coronavirus spike proteins |
| US10111948B2 (en) * | 2014-04-25 | 2018-10-30 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
| CA2961179A1 (en) | 2014-09-14 | 2016-03-17 | Washington University | Personalized cancer vaccines and methods therefor |
| WO2016090177A1 (en) * | 2014-12-03 | 2016-06-09 | Verik Bio, Inc. | Identification, selection and use of high curative potential t cell epitopes |
| TW201636358A (zh) * | 2014-12-09 | 2016-10-16 | 腫瘤療法 科學股份有限公司 | 對於ｔｈ１細胞之ｇｐｃ３抗原決定位胜肽及含此之疫苗 |
| CA3172682A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| US11090332B2 (en) | 2015-05-21 | 2021-08-17 | Regen BioPharma, Inc. | Antigen specific mRNA cellular cancer vaccines |
| AU2016339035A1 (en) * | 2015-10-12 | 2018-05-10 | Nantomics, Llc | Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors |
| GB201604755D0 (en) | 2016-03-21 | 2016-05-04 | Vaxeal Res Sas | Immunogenic compositions |
| IL265834B2 (en) | 2016-10-07 | 2023-03-01 | Univ Texas | hla-restricted vgll1 peptides and their use |
| WO2018138257A1 (en) | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| EP3369431A1 (en) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Vaccine |
| EP3370065A1 (en) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Immunogenic peptides |
| BR112019018307A2 (pt) | 2017-03-03 | 2020-03-31 | Treos Bio Zrt | Plataforma para identificação de peptídeos imunogênicos baseada em população |
| AU2018395397A1 (en) | 2017-12-28 | 2020-08-06 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| CN112512538A (zh) | 2018-05-18 | 2021-03-16 | 国家儿童医疗中心 | 改进的靶向t细胞疗法 |
| US20210213066A1 (en) | 2018-05-18 | 2021-07-15 | Children's National Medical Center | Improved cell therapy compositions for hematopoietic stem cell transplant patients |
| CN113329761A (zh) | 2018-09-04 | 2021-08-31 | 特雷斯生物有限公司 | 肽疫苗 |
| GB201814361D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Immunogenetic cancer screening test |
| GB201814362D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
| WO2020146434A2 (en) | 2019-01-07 | 2020-07-16 | Children's National Medical Center | Ex vivo activated t-lymphocytic compositions and methods of using the same |
| US12590292B2 (en) | 2019-01-07 | 2026-03-31 | Children's National Medical Center | Targeted T-cell therapy for treatment of multiple myeloma |
| GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
-
2018
- 2018-03-02 BR BR112019018307-8A patent/BR112019018307A2/pt unknown
- 2018-03-02 MX MX2019010460A patent/MX2019010460A/es unknown
- 2018-03-02 SG SG11201906765UA patent/SG11201906765UA/en unknown
- 2018-03-02 CN CN201880014727.1A patent/CN110651188B/zh active Active
- 2018-03-02 WO PCT/EP2018/055232 patent/WO2018158457A1/en not_active Ceased
- 2018-03-02 EP EP18710392.4A patent/EP3589951A1/en active Pending
- 2018-03-02 IL IL268919A patent/IL268919B2/en unknown
- 2018-03-02 AU AU2018226566A patent/AU2018226566B2/en active Active
- 2018-03-02 MA MA047683A patent/MA47683A/fr unknown
- 2018-03-02 KR KR1020197029092A patent/KR102549625B1/ko active Active
- 2018-03-02 MX MX2019010461A patent/MX2019010461A/es unknown
- 2018-03-02 CN CN202411399993.4A patent/CN119371510A/zh active Pending
- 2018-03-02 EP EP18707724.3A patent/EP3589954A1/en active Pending
- 2018-03-02 SG SG11201907524UA patent/SG11201907524UA/en unknown
- 2018-03-02 MA MA047677A patent/MA47677A/fr unknown
- 2018-03-02 BR BR112019018313-2A patent/BR112019018313A2/pt unknown
- 2018-03-02 BR BR112019018312-4A patent/BR112019018312A2/pt active Search and Examination
- 2018-03-02 JP JP2019568814A patent/JP7751374B2/ja active Active
- 2018-03-02 SG SG11201907402SA patent/SG11201907402SA/en unknown
- 2018-03-02 US US15/910,930 patent/US20180264094A1/en not_active Abandoned
- 2018-03-02 US US15/910,988 patent/US10213497B2/en active Active
- 2018-03-02 AU AU2018228786A patent/AU2018228786B2/en active Active
- 2018-03-02 JP JP2019568816A patent/JP7437939B2/ja active Active
- 2018-03-02 WO PCT/EP2018/055231 patent/WO2018158456A1/en not_active Ceased
- 2018-03-02 EP EP18707725.0A patent/EP3589310A1/en active Pending
- 2018-03-02 IL IL268920A patent/IL268920B2/en unknown
- 2018-03-02 KR KR1020197029093A patent/KR102723248B1/ko active Active
- 2018-03-02 MA MA047678A patent/MA47678A/fr unknown
- 2018-03-02 WO PCT/EP2018/055230 patent/WO2018158455A1/en not_active Ceased
- 2018-03-02 KR KR1020197029094A patent/KR102591136B1/ko active Active
- 2018-03-02 US US15/910,965 patent/US20180264095A1/en not_active Abandoned
- 2018-03-02 CA CA3054871A patent/CA3054871A1/en active Pending
- 2018-03-02 AU AU2018228785A patent/AU2018228785B2/en active Active
- 2018-03-02 CN CN201880014745.XA patent/CN110651189B/zh active Active
- 2018-03-02 KR KR1020247034375A patent/KR20240156643A/ko active Pending
- 2018-03-02 CA CA3054861A patent/CA3054861A1/en active Pending
- 2018-03-02 CA CA3054866A patent/CA3054866A1/en active Pending
- 2018-03-02 CN CN201880014739.4A patent/CN110621334A/zh active Pending
- 2018-03-02 JP JP2019568815A patent/JP7831948B2/ja active Active
- 2018-03-02 MX MX2019010459A patent/MX2019010459A/es unknown
-
2019
- 2019-01-10 US US16/244,497 patent/US11213578B2/en active Active
- 2019-07-18 ZA ZA2019/04725A patent/ZA201904725B/en unknown
- 2019-07-18 ZA ZA2019/04723A patent/ZA201904723B/en unknown
- 2019-08-26 IL IL268917A patent/IL268917B2/en unknown
- 2019-09-03 CL CL2019002534A patent/CL2019002534A1/es unknown
- 2019-09-03 CL CL2019002532A patent/CL2019002532A1/es unknown
- 2019-09-03 CL CL2019002533A patent/CL2019002533A1/es unknown
- 2019-09-26 CO CONC2019/0010524A patent/CO2019010524A2/es unknown
- 2019-09-26 CO CONC2019/0010503A patent/CO2019010503A2/es unknown
- 2019-09-27 CO CONC2019/0010698A patent/CO2019010698A2/es unknown
-
2021
- 2021-09-17 US US17/448,020 patent/US20220031823A1/en not_active Abandoned
- 2021-11-09 US US17/454,225 patent/US20220072114A1/en not_active Abandoned
- 2021-12-22 US US17/645,741 patent/US11628211B2/en active Active
- 2021-12-22 US US17/645,737 patent/US11426452B2/en active Active
-
2022
- 2022-10-14 CL CL2022002836A patent/CL2022002836A1/es unknown
- 2022-12-09 JP JP2022197534A patent/JP2023051941A/ja active Pending
-
2023
- 2023-02-08 US US18/166,420 patent/US20230405100A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510698A5 (enExample) | ||
| IL268917B2 (en) | A population-based immunogenic peptide identification platform | |
| AU2022241521A1 (en) | Shared neoantigens | |
| SA519401562B1 (ar) | بروتينات دمج FC دايمرية غير متجانسة لـ IL15/IL15Rα | |
| McGonagle et al. | 'MHC-I-opathy'—unified concept for spondyloarthritis and Behçet disease | |
| BR112021007626A2 (pt) | Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d) | |
| ES2569240T3 (es) | Polipéptidos y anticuerpos obtenidos a partir de células de leucemia linfocítica crónica y usos de los mismos | |
| JP2022502371A5 (enExample) | ||
| ES2573115T3 (es) | Nuevo anticuerpo anti-DR5 | |
| JP2016196468A5 (enExample) | ||
| JP2019511222A5 (enExample) | ||
| JP2020536488A5 (enExample) | ||
| JP7486953B2 (ja) | 細胞標的化療法のための組成物および方法 | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| JP2013503205A5 (enExample) | ||
| JP2005503789A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| UA126441C2 (uk) | Химерні антигенні рецептори, націлені на bcma, та способи їх застосування | |
| JP2018529359A5 (enExample) | ||
| RU2006144820A (ru) | Антитела, связывающиеся с рецепторами kir2dl1,-2,-3 и не связывающиеся с рецептором kir2ds4, и их терапевтическое применение | |
| TW200831533A (en) | Interleukin-13 binding proteins | |
| RU2016124179A (ru) | СКОНСТРУИРОВАННЫЕ ВЫСОКОАФФИННЫЕ T-клеточные рецепторы человека | |
| JP2017537627A5 (enExample) | ||
| JP2013506425A5 (enExample) | ||
| AU2015314776A1 (en) | Personalized cancer vaccines and methods therefor |